Strikingly, in both cancer types, we observed a statistically significant higher proportion of myeloid cells with high expression levels of TREM1 myeloid signature in the peripheral blood of non-responders compared to responders of immune checkpoint blockade therapy (Supplementary Figs. 5h, i), suggesting the prognostic value of the tumor-associated TREM1 myeloid signature. The gene discussed is TREM1; the disease is cancer.